Major Depressive Disorder
Failed two lines of anti depressant treatment
Between 18-65 years of age
Any metallic implant
Bipolar Disorder or Psychotic Disorder
Heavy alcohol or recreational drug use
Inflammatory disease like Lupus, Rheumatoid Arthritis

>= age 13
read and speak English
neurological disorders
developmental disorders
Autism

18-25 years old
Weigh less than 250 lbs.
Fluent English speaker
Metal in body
Neurological disorder (autism, developmental disorder)
Current pregnancy
Less than 20/40 far acuity (corrected or uncorrected)

Participants must be between the ages of 18 and 45.
Participants must be right handed.
Participants must be fluent English speakers.
Participants must have a body mass index (BMI) >= 25.
Participants must have experienced food eating/weight issues.
If participants are currently engaging in active dieting behaviors (e.g., a weight loss program) or they are taking medications that could alter appetite or body weight.
If participant have a lifetime history of diagnosed eating disorders, diabetes, hyperglycemia, high levels of triglycerides, or high cholesterol or other related medical conditions.
If participants have any known risk from exposure to high-field strength magnetic fields (e.g., pace makers), any irremovable metallic foreign objects in their body (e.g., braces), or a questionable history of metallic fragments.
If participants report that they are vegetarian/vegan.
If participants are not willing to refrain from using alcohol for 24 hours or from using nicotine products/recreational drugs for 3 weeks, or unwilling to fast from food for 5 hours prior to two of three lab visits.

infant is at least 3.5 months of age
infant born within +/- 3 weeks of due date
Infants without any serious medical complications
Infants of a healthy birth weight (>2500g; >5 lbs, 8 oz.)
infant not of healthy gestational age
infants <2500g; <5lbs, 8 oz at birth
Infants who experienced any serious medical complications

Children aged 8-12
Children outside of the 8-12 age range
History of seizures or photosensitive epilepsy

Over the age of 18
Monolingual speaker of English OR
Bilingual speaker of English and at least one other language
Normal hearing
Right-handed
Under the age of 18
Does not speak English
Hearing loss
History of head injury, stroke, TBI, or seizure

Patient must have a subjective memory concern as reported by patient, study partner, or clinician
Age 55-90 (inclusive)
Study Partner is available who has frequent contact with the patient (e.g. an average of 10 hours per week or more), and can accompany the patient to most visits to answer questions about the patient
Must speak English fluently
Good general health with no additional diseases/disorders expected to interfere with the study
Any use of tobacco or nicotine products within the past year
Any significant neurologic disease such as Alzheimer’s disease dementia, Parkinson’s disease, multi-infarct dementia, brain tumor, seizure disorder, etc.
History of alcohol or substance abuse or dependence within the past 2 years

Histopathologically confirmed WHO grade IV recurrent astrocytoma (recurrent GBM)
Recurrent surgically resectable tumor
Estimated survival of at least 3 months;
Subjects with newly diagnosed GBM
Pregnant women or nursing mothers cannot participate in the study. Women of childbearing age must have a negative pregnancy test within 72 hours prior to study entry.

Age 18 years and older
Diagnosis of or suspected diagnosis of glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)
Patient must undergo elective surgery or biopsy to remove tumor tissue
Consideration as a candidate for systemic therapy with cytotoxic chemotherapy, targeted small molecule inhibitors or immunotherapy
Age of <18 years
Do not have a diagnosis of or suspected diagnosis of glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)
Patient will not have surgery or a biopsy as part of routine clinical practice
Patient has known active cancer metastatic to the brain except for patients with brain metastases that have been treated and are considered stable
Patient refuses to have the assay performed on their tissue

Between the ages of 30-65
Able and willing to undergo an MRI
Able to travel to State College for the Study
Current psychotherapy treatment for depression
Started anti-depressant medication in the last 2 months
Diagnosis of bipolar disorder, schizophrenia, or significant neurocognitive impairment
Very severe depression that would interfere with the ability to participate or suicidal ideations
Unable to undergo an MRI (metal in your body)

18-55 years of age
Right Handed
Smokes cigarettes
under 18 years of age or over 55 years of age
Left Handed
non-smokers

Native English speaker
Normal vision and hearing (with correction)
Free of neuroneurologic, psychiatric, endocrinology disorders
Free of concussions with loss of consciousness
Family history of autism spectrum disorders (in parents or full siblings)
History of working with metal
Irremovable metallic implants in the body (e.g. braces)
Pregnancy
Weigh more than 250lbs or get claustrophobic in small spaces

Male subjects 21 to 65 years of age
Subjects weighing between 110 to 240 pounds; their body mass index (BMI) should be in the range of 19=< BMI >=30
Subjects having normal hepatic, renal function as assessed by history, physical and clinical chemistry analysis (CMP eGFR).
Subjects with normal blood pressure (systolic below 120 mm Hg and diastolic below 80 mm Hg)
Subjects positive for HIV, HBV and HCV (self-reported)
Subjects taking any kind of prescription medications regularly or within 10 days of the study will be excluded.
Subjects taking dietary or herbal supplements that contain AGN (e.g. Cogni.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) within 10 days of the study.
Non-English-speaking subjects

Age ≥ 18 years.
ECOG performance status of 0 or 1.
Patients must have oropharynx cancer that is p16-positive by immunohistochemistry
Adequate baseline organ and marrow function
Adequate baseline liver functionality
Patients with a history of allergic reactions attributed to platinum based chemotherapy agents
Patients must not have had prior systemic therapy or radiation treatment for p16 positive OPSCC
Patients must not have received previous irradiation for head and neck, tumor, skull base, or brain tumors
Patients must not have known hypersensitivity to nivolumab
Patients with evidence of distant metastases or leptomeningeal disease are excluded

Graduate Students
Major in disciplines related to Earth Sciences (e.g., Geosciences, Geography, and Environmental Science)
Younger than 18 years old